NutriBand Inc. (NTRB) stock
Close on Nov 11, 2026Market cap $72.20MP/E –Yield –
NutriBand Inc. saw revenue fall 37.3% to $1.62M over the twelve months to Jul 31, 2026. Free cash flow was -$5.14M. At the latest close the market valued the company at $72.20M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $72.20M
- P/E ratio
- –
- Price to sales
- 44.63
- Price to book
- 13.55
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.62M
- Net income
- -$6.96M
- EPS, diluted
- -$0.57
- Free cash flow
- -$5.14M
- Book value per share
- $0.44
- Diluted shares
- 12M
Trading
- Previous close
- $5.76
- Open
- $5.56
- Day's range
- $5.56 – $6.00
- Volume
- 7,584
- Average volume (20 days)
- 26,226
- Beta (5 years)
- 1.73
- 52-week range
- $2.80 – $9.19
- RSI (14 days)
- 47.2
- Volatility (1 year)
- 79.1%
- Relative volume
- 0.14×
- WACC
- 13.5%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NTRB | S&P 500 | Difference | NTRB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.7% | -2.4% | −8.3 pts | ||
| 3 months | +86.8% | -1.2% | +87.9 pts | ||
| Year to date | +30.8% | +12.3% | +18.5 pts | ||
| 1 year | -2.5% | +12.4% | −14.9 pts | ||
| 3 years | +166.4% | +78.8% | +87.6 pts | +38.6% | +21.4% |
| 5 years | +15.8% | +75.2% | −59.3 pts | +3.0% | +11.9% |
Eleven years at a glance
Fiscal years 2016 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NutriBand filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About NutriBand
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Nutriband Inc. is a pharmaceutical company that develops transdermal drug delivery systems, focusing on abuse-deterrent technologies. Its proprietary AVERSA platform incorporates aversive agents into patches to prevent the misuse and accidental exposure of opioids and stimulants. The development pipeline includes transdermal fentanyl, buprenorphine, and methylphenidate. Nutriband operates through two segments: Pocono Pharmaceuticals and 4P Therapeutics. Pocono provides contract manufacturing services for health, wellness, and over-the-counter pharmaceutical clients, while 4P Therapeutics conducts contract research and development for pharmaceutical and medical device customers.
Company profile, executives and historyNutriBand stock: common questions
What is NutriBand's stock price?
NTRB closed at $5.94 on Nov 11, 2026, up 3.13% on the day. Over the past 52 weeks it traded between $2.80 and $9.19.
What is NutriBand's market cap?
NutriBand was worth $72.20M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NTRB's P/E ratio?
NutriBand lost money over the twelve months to Jul 31, 2026 (diluted EPS -$0.57), so it has no meaningful P/E ratio.
How much revenue does NutriBand make?
NutriBand reported revenue of $1.62M for the twelve months to Jul 31, 2026, down 37.3% from a year earlier.
Does NutriBand pay a dividend?
No. NutriBand has not paid a cash dividend over the last twelve months.
How has NTRB stock performed over the past year?
Including dividends, NTRB returned -2.5% over the past year, against +12.4% for the S&P 500.
How many NTRB shares are sold short?
0M shares were sold short at the latest FINRA report, 1.51% of the float, or 4.9 days of average trading volume.
Who are NutriBand's competitors?
Companies most similar to NutriBand by business, industry and size include FEED, CLGN, MLSS, PLSE, INBS.
See a number that looks wrong?